Tricyclic compounds for treatment of hsv
Tricyclic compounds targeting the viral helicase-primase complex provide a novel solution for treating HSV infections, addressing the limitations of current treatments by enhancing efficacy and safety.
WO2026035901A1 Publication Date: 2026-02-12ASSEMBLY BIOSCIENCES INC
9 Cites 1 Cited by
Patent Information
- Application Number
- PCT/US2025/040994
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-07
- Filing Date
- 2025-08-06
- Publication Date
- 2026-02-12
AI Technical Summary
Technical Problem
Current treatments for HSV infections, such as nucleoside analogues, are inadequate in preventing recurrent outbreaks, have adverse effects, and are ineffective against TK-deficient viruses, necessitating the development of safer and more potent antiviral compounds.
Method used
Development of tricyclic compounds that inhibit the viral helicase-primase complex, providing a novel mechanism of action against HSV1 and HSV2, including formulations and administration methods to enhance therapeutic efficacy.
Benefits of technology
The tricyclic compounds effectively treat and prevent HSV infections, including resistant strains, with reduced adverse effects and improved bioavailability, offering a safer and more effective alternative to existing therapies.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.
Need to check novelty before this filing date? Find Prior Art